Schering-Plough’s “Faster” Claims For Lotrimin Ultra Not Accurate – NAD
This article was originally published in The Tan Sheet
Schering-Plough Healthcare Products should modify claims that its Lotrimin Ultra relieves athlete's foot in less time than Novartis Consumer Healthcare's Lamisil Defense, the National Advertising Division recommends
You may also be interested in...
Novartis Consumer Health should modify claims for its Lamisil AT Gel Advanced athlete's foot treatment to emphasize the product has been proven effective in between the toes only, the National Advertising Division states in a decision announced March 3
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.